

# Resource Summary Report

Generated by [SPARC SAWG](#) on Aug 16, 2026

## MSGV1-1D3-28Z.1-3 mut

RRID:Addgene\_107227

Type: Plasmid

### Proper Citation

RRID:Addgene\_107227

### Plasmid Information

**URL:** <http://www.addgene.org/107227>

**Proper Citation:** RRID:Addgene\_107227

**Insert Name:** 1D3-28Z. 1-3 mut

**Organism:** Synthetic

**Bacterial Resistance:** Ampicillin

**Defining Citation:** [PMID:20631379](#)

**Vector Backbone Description:** Backbone Size:5586; Vector Backbone:MSGV1; Vector Types:Retroviral; Bacterial Resistance:Ampicillin

**Plasmid Name:** MSGV1-1D3-28Z.1-3 mut

**Relevant Mutation:** None

**Record Creation Time:** 20220422T221520+0000

**Record Last Update:** 20260815T080108+0000

### Ratings and Alerts

No rating or validation information has been found for MSGV1-1D3-28Z.1-3 mut.

No alerts have been found for MSGV1-1D3-28Z.1-3 mut.

### Data and Source Information

**Source:** [Addgene](#)

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [SPARC SAWG](#) .

Schwingen NR, et al. (2026) Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences. *Frontiers in immunology*, 17, 1787951.

Oh S, et al. (2023) Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. *Nature biotechnology*, 41(9), 1229.

Luo W, et al. (2022) Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies. *Frontiers in immunology*, 13, 816761.

Ma Y, et al. (2022) Identification and assessment of TCR-T cells targeting an epitope conserved in SARS-CoV-2 variants for the treatment of COVID-19. *International immunopharmacology*, 112, 109283.

Nguyen NT, et al. (2021) Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. *Nature nanotechnology*, 16(12), 1424.

Ma Y, et al. (2021) Next Generation Sequencing-Based Identification of T-Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma. *Hepatology communications*, 5(6), 1106.